News
ATXS
9.56
+1.16%
0.11
Astria Therapeutics Expands Stock Incentive Plan
TipRanks · 1d ago
Weekly Report: what happened at ATXS last week (1209-1213)?
Weekly Report · 5d ago
Astria Therapeutics’ Navenibart Shows Promising Results in HAE Prophylaxis, Earning Buy Rating
TipRanks · 12/11 19:55
HC Wainwright & Co. Reiterates Buy on Astria Therapeuticsto Buy
Benzinga · 12/11 17:50
Astria Therapeutics price target raised to $32 from $28 at Oppenheimer
TipRanks · 12/11 16:55
Astria Therapeutics announces final results from ALPHA-STAR trial
TipRanks · 12/11 13:10
ASTRIA THERAPEUTICS: ADVANCING NAVENIBART TO PHASE 3 DEVELOPMENT WITH TRIAL INITIATION EXPECTED IN Q1 2025
Reuters · 12/11 13:00
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Dow Jones · 12/10 17:26
HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target
Benzinga · 12/10 17:16
Astria Therapeutics: Strategic Advances and Regulatory Milestones Drive Buy Rating
TipRanks · 12/10 15:15
Astria Therapeutics announces FDA clearance for STAR-0310 IND application
TipRanks · 12/10 13:11
Astria Therapeutics Announces FDA Clearance Of IND Application For STAR-0310, A Monoclonal Antibody OX40 Antagonist For The Treatment Of Atopic Dermatitis
Benzinga · 12/10 13:06
ASTRIA THERAPEUTICS INC: EARLY PROOF-OF-CONCEPT RESULTS EXPECTED IN Q3 2025
Reuters · 12/10 13:00
Weekly Report: what happened at ATXS last week (1202-1206)?
Weekly Report · 12/09 11:14
Weekly Report: what happened at ATXS last week (1125-1129)?
Weekly Report · 12/02 11:15
Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema
Seeking Alpha · 11/27 13:00
Weekly Report: what happened at ATXS last week (1118-1122)?
Weekly Report · 11/25 11:07
TD Cowen Reaffirms Their Buy Rating on Astria Therapeutics (ATXS)
TipRanks · 11/20 12:26
Weekly Report: what happened at ATXS last week (1111-1115)?
Weekly Report · 11/18 11:04
Astria Therapeutics Reports Q3 2024 Financial Results
TipRanks · 11/16 03:56
More
Webull provides a variety of real-time ATXS stock news. You can receive the latest news about Astria Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About ATXS
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.